Drugs / HRS-2329
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07189949 | Oct 2025 → Dec 2028 expected | — | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HRS-2329 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07189949 ↗ |
| Route | Oral | “Oral HRS-2329 tablet.” NCT07189949 ↗ |